Alnylam Pharmaceuticals
Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Health Care
Alnylam Pharmaceuticals, Inc. is a leading RNAi therapeutics company focused on developing novel medicines to treat genetically defined diseases. The company is committed to bringing innovative treatments to patients suffering from serious conditions. Their investigational product vutrisiran is designed to treat transthyretin amyloidosis with cardiomyopathy, aiming to improve patient outcomes thro
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 2,555
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (ALNY)
- Website
- www.alnylam.com
- Company page
Recent activity at Alnylam Pharmaceuticals
- : Alnylam Pharmaceuticals Partners with Inceptive Nucleics to Enhance RNAi Drug Discovery Using AI.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On March 2, 2026, Alnylam Pharmaceuticals, Inc. granted a special equity award to Dr. Yvonne Greenstreet, the Chief Executive Officer, as part of its strategy to retain and incentivize her leadership. This Special Award was granted under the Company's 2018 Stock Incentive Plan and is fully performance-based, contingent on achieving significant stock price appreciation by December 31, 2029. The Board recognized Dr. Greenstreet's key role in the Company's past successes, including close to 100% stockholder returns and the strategic launch of AMVUTTRA, while setting ambitious future goals encapsulated in 'Alnylam 2030'. The award also aligns Dr. Greenstreet’s incentives with the long-term interests of stockholders, marking an important step in ensuring stable leadership as Alnylam progresses in its growth phase.
- : SEC 8-K (8.01): On December 10, 2025, Alnylam Pharmaceuticals, Inc. entered into repurchase agreements for its 1.00% convertible senior notes due 2027. The company agreed to repurchase approximately $34.4 million of the Notes for a total cost of approximately $51.9 million, with the final repurchase price subject to adjustments based on the daily volume-weighted average price of the company's stock starting December 11, 2025. The transaction is expected to close shortly after the measurement period, pending customary closing conditions, leaving approximately $362.8 million of the Notes outstanding thereafter. The repurchases are part of the company's strategic financial management and are expected to have implications for its capital structure and future funding strategies.
- : SEC 8-K (5.02): On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. resigned from the Board of Directors of Alnylam Pharmaceuticals, Inc., effective immediately, without any disagreement with the Company. Following these resignations, the Board decreased the number of directors from eleven to ten and elected Stuart A. Arbuckle as a non-employee director, effective January 5, 2026. Mr. Arbuckle will receive a cash retainer of $75,000 and a stock option grant valued at $600,000, with specific vesting terms. He is also eligible for an annual equity award and will receive reimbursements for related expenses incurred during his directorship. This event has strategic implications for the Board's composition and governance structure.
- : SEC 8-K (5.02): On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. resigned from the Board of Directors of Alnylam Pharmaceuticals, Inc. Their resignations were effective immediately and were not due to any disagreements regarding the Company's operations or policies. Following their departure, the Board approved a reduction in the number of directors from eleven to ten, reflecting the updated governance structure. This change may impact the Board's decision-making and governance dynamics moving forward.
- : Alnylam Pharmaceuticals Appoints Pushkal Garg as Chief Research and Development Officer
- : Alnylam Receives FDA Approval for AMVUTTRA® (vutrisiran) to Treat ATTR-CM and hATTR-PN
- : Alnylam Pharmaceuticals announces preliminary fourth quarter and full year 2024 global net product revenues and outlines 2025 goals.
Leadership
- Pushkal Garg, Chief Research Officer
Verified email and direct lines for Alnylam Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Alnylam Pharmaceuticals files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Alnylam Pharmaceuticals in the news
- Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress - Alnylam (Oct 29, 2026)
- Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress - Alnylam (Apr 30, 2026)
- Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress - Alnylam (Jul 30, 2026)
- Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growi - Alnylam (Dec 17, 2025)
- Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular - Alnylam (Mar 20, 2025)
- Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity - Alnylam (Oct 27, 2022)
- Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Sign - Alnylam (Jun 24, 2024)
- Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day - Alnylam (Dec 13, 2023)
Companies similar to Alnylam Pharmaceuticals
- Foresee Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Daiichi Sankyo · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Supernus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apellis Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Alnylam Pharmaceuticals: questions and answers
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals, Inc. is a leading RNAi therapeutics company focused on developing novel medicines to treat genetically defined diseases. The company is committed to bringing innovative treatments to patients suffering from serious conditions. Their investigational product vutrisiran is designed to treat transthyretin amyloidosis with cardiomyopathy, aiming to improve patient outcomes thro
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.
How many employees does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has about 2,555 employees.
What is the latest news on Alnylam Pharmaceuticals?
On Jun 04, 2026, Alnylam Pharmaceuticals Partners with Inceptive Nucleics to Enhance RNAi Drug Discovery Using AI.
Is Alnylam Pharmaceuticals a public company?
Yes. Alnylam Pharmaceuticals is publicly traded under the ticker ALNY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy